



(51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61K 38/17* (2006.01)
C12N 15/62 (2006.01)

(74) **Agent:** GIBSON, Mark et al.; Sagittarius IP, Three Globe-
side, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ
(GB).

(21) **International Application Number:**
PCT/GB2017/051303

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) **International Filing Date:**
10 May 2017 (10.05.2017)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
1608197.8 10 May 2016 (10.05.2016) GB

(71) **Applicant:** DUCENTIS BIOTHERAPEUTICS LTD.
[GB/GB]; 9 Blenheim Lane, Freeland, Witney Oxfordshire
OX29 8AW (GB).


(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(72) **Inventors:** HUXLEY, Philip; c/o Ducentis Biotherapeu-
tics Ltd., 9 Blenheim Lane, Freeland, Witney Oxfordshire
OX29 8AW (GB). SHERIDAN, Joseph; c/o Ducentis Bio-
therapeutics Ltd., 9 Blenheim Lane, Freeland, Witney Ox-
fordshire OX29 8AW (GB). HEAL, Jonathan; c/o Ducen-
tis Biotherapeutics Ltd., 9 Blenheim Lane, Freeland, Wit-
ney Oxfordshire OX29 8AW (GB).

(54) **Title:** CD200 MUTANT AND ITS USES

FIGURE 6

Dose response results comparing the inhibition of PMA stimulated oxidative
burst in isolated human neutrophils by wild-type CD200-Fc and K130Y



(57) **Abstract:** The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein encoding portion via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with amended claims and statement (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))